respiratory

News

Respiratory biotech Upstream joins Nasdaq IPO surge

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.

News

Tobacco firm PMI divests Vectura at a loss after backlash

Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years a

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

News

Businessmen gesticulating and discussing contents on a smartphone

ERS: Analysis of speech spots COPD flare-ups

Researchers have found that changes in speech recorded using a smartphone can be used to predict when a patient with chronic obstructive pulmonary disease (COPD) is at risk of an exacerbati

News

ERS: GSK reveals data behind new asthma hope depemokimab

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS

News

GSK joins Flagship's flotilla of pharma partners

Flagship Pioneering has signed yet another strategic-level deal with a big pharma group, with GSK the latest to tap into its network of biotech companies in an alliance that could be worth

Respiratory biotech Upstream joins Nasdaq IPO surge

Tobacco firm PMI divests Vectura at a loss after backlash

Trial sets up filings for Boehringer IPF drug nerandomilast

ERS: Analysis of speech spots COPD flare-ups

ERS: GSK reveals data behind new asthma hope depemokimab

GSK joins Flagship's flotilla of pharma partners

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

respiratory

Editor's Picks